KIT and gastrointestinal stromal tumor: Of note, in terms of an RS-based classification of GIST with K11-PM/D, clinicians must be cautious about starting standard Imatinib therapy, as only 63.6% of estimated K11-PM/D in the TC and 63.0% in the VC was histologically confirmed to be true KIT-11 K11-PM/D.